RTP Mobile Logo
Select Publications

Altorki N et al. IMpower010: Characterization of stage IB-IIIA NSCLC patients by type and extent of therapy prior to adjuvant atezolizumab. World Conference on Lung Cancer 2021;Abstract PL02.05.

Balaji A et al. Steroid-refractory PD-(L)1 pneumonitis: Incidence, clinical features, treatment, and outcomes. J Immunother Cancer 2021;9(1):e001731. Abstract

Besse B. Invited discussant LBA9. ESMO 2021;Abstract.

Brown VT et al. Real-world incidence and management of immune-related adverse events from immune checkpoint inhibitors: Retrospective claims-based analysis. Cancer Invest 2021;39(10):789-96. Abstract

Chen X et al. Radiation versus immune checkpoint inhibitor associated pneumonitis: Distinct radiologic morphologies. Oncologist 2021;26(10):e1822-32. Abstract

Cho BC et al. Updated analysis and patient-reported outcomes (PROs) from CITYSCAPE: A randomised, double-blind, phase II study of the anti-TIGIT antibody tiragolumab + atezolizumab (TA) versus placebo + atezolizumab (PA) as first-line treatment for PD-L1+ NSCLC. ESMO Immuno-Oncology 2021;Abstract LBA2.

Felip E et al. IMpower010: Sites of relapse and subsequent therapy from a phase III study of atezolizumab vs best supportive care after adjuvant chemotherapy in stage IB-IIIA NSCLC. ESMO 2021;Abstract LBA9.

Felip E et al. Adjuvant atezolizumab after adjuvant chemotherapy in resected stage IB-IIIA non-small-cell lung cancer (IMpower010): A randomised, multicentre, open-label, phase 3 trial. Lancet 2021;398(10308):1344-57. Abstract

Fitzpatrick O, Naidoo J. Immunotherapy for stage III NSCLC: Durvalumab and beyond. Lung Cancer (Auckl) 2021;12:123-31. Abstract

Friedlaender A et al. Role and impact of immune checkpoint inhibitors in neoadjuvant treatment for NSCLC. Cancer Treat Rev 2022;104:102350. Abstract

Gogishvili M et al. EMPOWER-Lung 3: Cemiplimab in combination with platinum doublet chemotherapy for first-line (1L) treatment of advanced non-small cell lung cancer (NSCLC). ESMO 2021;Abstract LBA51.

Naidoo J. Microbiome racial disparities and neoadjuvant strategies. ASCO 2021;Abstract.

Passiglia F et al. Major breakthroughs in lung cancer adjuvant treatment: Looking beyond the horizon. Cancer Treat Rev 2021;101:102308. Abstract

Rodriguez-Abreu D et al. Primary analysis of a randomized, double-blind, phase II study of the anti-TIGIT antibody tiragolumab (tira) plus atezolizumab (atezo) versus placebo plus atezo as first-line (1L) treatment in patients with PD-L1-selected NSCLC (CITYSCAPE). ASCO 2020;Abstract 9503.

Schneider BJ et al. Management of immune-related adverse events in patients treated with immune checkpoint inhibitor therapy: ASCO Guideline Update. J Clin Oncol 2021;39(36):4073-126. Abstract

Sezer A et al. Cemiplimab monotherapy for first-line treatment of advanced non-small-cell lung cancer with PD-L1 of at least 50%: A multicentre, open-label, global, phase 3, randomised, controlled trial. Lancet 2021;397(10274):592-604. Abstract

Spigel DR et al. Five-year survival outcomes from the PACIFIC Trial: Durvalumab after chemoradiotherapy in stage III non-small-cell lung cancer. J Clin Oncol 2022;[Online ahead of print]. Abstract

Taylor MH et al. Phase IB/II trial of lenvatinib plus pembrolizumab in patients with advanced renal cell carcinoma, endometrial cancer, and other selected advanced solid tumors. J Clin Oncol 2020;38(11):1154-63. Abstract